指南与共识糖尿病

妊娠期糖尿病技术应用国际共识:CGM与自动胰岛素输注

Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement.
指南 / 共识 · Lancet Diabetes Endocrinol · 2025-12-17

该国际共识声明针对1型、2型和妊娠期糖尿病孕妇,评估持续葡萄糖监测(CGM)与自动胰岛素输注(AID)技术的应用。共识强调CGM在孕前和孕期对1型糖尿病孕妇减少妊娠并发症的价值,并推荐AID系统用于孕前、孕期、分娩及产后改善血糖管理。声明由24个学会和团体背书。

要点

  • CGM在孕前和孕期用于1型糖尿病孕妇可减少妊娠并发症。
  • 推荐1型糖尿病孕妇使用AID系统改善孕前、孕期、分娩及产后血糖管理。
  • 妊娠期和2型糖尿病的CGM诊断阈值及目标范围尚待确定。

核心结论

  • 共识强调CGM在孕前和孕期对1型糖尿病孕妇减少妊娠并发症的价值。
  • 推荐1型糖尿病孕妇使用AID系统改善孕前、孕期、分娩及产后血糖管理。
  • 妊娠期糖尿病和2型糖尿病的CGM诊断阈值及目标范围仍需确定。

研究设计与样本

  • 该共识声明由24个学会和团体背书。
  • 基于现有证据形成推荐,未报告系统检索范围。

主要发现

  • 胰岛素抵抗在妊娠早期后增加,给孕前1型或2型糖尿病女性带来血糖挑战。
  • 多数(>95%)糖尿病女性分娩健康婴儿,但母体血糖异常可导致母婴并发症。
  • CGM和AID在妊娠外可优化血糖,但缺乏大规模随机对照试验验证。
  • 有令人信服的数据报告CGM在1型糖尿病中的益处,以及AID在1型糖尿病妊娠中日益增多的数据。

关键数值与推荐

  • 妊娠期糖尿病诊断的适当CGM葡萄糖阈值尚未确定。
  • 妊娠期糖尿病和2型糖尿病常规管理的推荐目标范围内时间尚待确定。

临床怎么用

  • 对孕前1型糖尿病女性,应在孕前和孕期使用CGM以减少妊娠并发症。
  • 对孕前1型糖尿病女性,推荐使用AID系统改善孕前、孕期、分娩及产后血糖管理。

局限性

  • CGM和AID尚未在孕前和孕期进行大规模随机对照试验广泛测试。
  • 妊娠期糖尿病和2型糖尿病的CGM诊断阈值及目标范围尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Insulin resistance increases after the first trimester of pregnancy, leading to glycaemic challenges for women with pregestational type 1 diabetes or type 2 diabetes. Additionally, insulin resistance can promote hyperglycaemia in pregnant women without type 1 diabetes or type 2 diabetes, who develop gestational diabetes. Although most (>95%) women with diabetes deliver healthy babies, maternal dysglycaemia can have consequences for the mother and child, including prenatal, perinatal, immediate, and long-term postnatal complications. Diabetes technologies, such as continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems can aid in optimising glycaemia outside of pregnancy. These novel technologies have not been extensively tested in large randomised controlled trials before and during pregnancy. However, compelling data report the benefits of CGM in type 1 diabetes, and increasing data report on AID systems in pregnancies complicated by type 1 diabetes. Appropriate CGM glucose thresholds for the diagnosis of gestational diabetes and the recommended time in range treatment targets for the routine management of gestational diabetes and type 2 diabetes still need to be determined. The recommendations in this Consensus Statement emphasise the value of CGM during preconception and pregnancy for women with pregestational type 1 diabetes in reducing pregnancy complications. Recommendations also include the use of AID systems in women with pregestational type 1 diabetes to improve glycaemic management during preconception, during pregnancy and delivery, and in the postpartum period. This Consensus Statement has been endorsed by 24 societies and groups.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Benhalima K, Durnwald C, Sweeting A, et al. Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement. Lancet Diabetes Endocrinol. 2025. PMID: 41421368. doi:10.1016/S2213-8587(25)00335-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。